

**CORONA Remedies Limited**

(Formerly known as CORONA Remedies Private Limited)

Regd. Office: CORONA House

C- Mondeal Business Park, Near Gurudwara, S.G. Highway,
Thaltej, Ahmedabad 380 059. Gujarat, India.

Tele.: +079 - 40233000

Online at : Info@coronaremedies.com

website : www.coronaremedies.com

CIN : L24231GJ2004PLC044656

January 02, 2026

To,
Listing Operation Department
BSE Limited
P. J. Towers,
Dalal Street, Mumbai - 400001
(BSE Scrip Code: 544644)

To,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla
Complex, Bandra (East), Mumbai– 400051
(NSE Scrip Code: CORONA)

Dear Sir / Madam,

Sub.: Outcome of the Board Meeting

Ref.: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), we would like to inform that the Board at its meeting held today has, inter alia, approved the unaudited standalone and consolidated financial results along with limited review reports of the Company for the second quarter and half year ended on September 30, 2025. The said financial results are enclosed herewith.

In terms of Regulation 47 of the Listing Regulations, the Company will publish an advertisement for unaudited standalone and consolidated financial results for the second quarter and half year ended on September 30, 2025.

The above results along with limited review reports are also being made available on the website of the Company at www.coronaremedies.com

A Press Release on financial results which is being submitted to the media, is also enclosed herewith.

The Board meeting commenced at 03:30 p.m. and concluded at 04:30 p.m.

You are requested to take note of the above.

Thanking you.

Yours Faithfully,

For **CORONA Remedies Limited**

Chetna Dharajiya
Company Secretary and Compliance Officer

Encl.: A/a

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF CORONA REMEDIES LIMITED (FORMERLY KNOWN AS CORONA REMEDIES PRIVATE LIMITED)

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **CORONA Remedies Limited (formerly known as CORONA Remedies Private Limited)** ("the Company"), for the quarter and half year ended September 30, 2025 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



**Deloitte
Haskins & Sells LLP**

5. As stated in Note 4 to the Statement, financial information relating to the quarter and half year ended September 30, 2024 included in the Statement have been furnished to us by the Management and have not been subjected to review by us.

Our conclusion on the Statement is not modified in respect of this matter.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



H. S. Sutaria

Hardik Sutaria
Partner
Membership No. 116642
UDIN: 26116642FIGOUY9493

Place: Ahmedabad
Date: January 02, 2026



CORONA Remedies Limited
 (formerly known as CORONA Remedies Private Limited)
 Regd. Office: CORONA House,
 C - Mondeal Business Park, Near Gurudwara, S.G.Highway,
 Thaltej, Ahmedabad-380059, Gujarat, India
 Tele.: +079-40233000 | Website : www.coronaremedies.com
 CIN : L24231GJ2004PLC044656

Statement of Unaudited Standalone Financial Results for the Quarter and Half Year ended 30 September 2025

(Amount Rs. in Crores except per share data)

Sr. No.	Particulars	For Quarter Ended			For Half Year Ended		For Year Ended
		30 Sept. 2025 (Unaudited)	30 June 2025 (Audited) (Refer note 5)	30 Sept. 2024 (Unaudited) (Refer note 4)	30 Sept. 2025 (Unaudited)	30 Sept. 2024 (Unaudited) (Refer note 4)	31 March 2025 (Audited)
1	Income :						
a	Revenue from operations	361.13	346.54	313.87	707.67	605.04	1,196.42
b	Other income	2.27	2.02	2.46	4.29	3.75	5.93
	Total income	363.40	348.56	316.33	711.96	608.79	1,202.35
2	Expenses :						
a	Cost of materials consumed	25.90	25.07	28.56	50.97	51.69	102.29
b	Purchases of Stock-in-trade	28.11	34.77	41.94	62.88	77.02	157.97
c	Changes in inventories of finished goods, stock-in-trade and work-in-progress	14.64	5.94	(7.90)	20.58	(4.25)	(23.74)
d	Employee benefits expense	103.00	97.44	87.82	200.44	171.82	346.14
e	Finance costs	1.93	1.99	2.87	3.92	6.02	10.60
f	Depreciation and amortization expenses	9.20	8.92	9.05	18.12	17.43	37.16
g	Other expenses	111.01	113.54	96.63	224.55	192.42	373.78
	Total expenses	293.79	287.67	258.97	581.46	512.15	1,004.20
3	Profit before tax (1-2)	69.61	60.89	57.36	130.50	96.64	198.15
4	Tax expense :						
a	Current tax expense	15.85	15.19	12.89	31.04	22.22	45.55
b	(Excess) provision for tax relating to earlier periods / year	-	(0.89)	(0.75)	(0.89)	(0.75)	(0.75)
c	Deferred tax expense / (income)	1.61	0.19	2.24	1.80	2.24	4.30
	Total Tax expense	17.46	14.49	14.38	31.95	23.71	49.10
5	Net Profit after tax for the period / year (3-4)	52.15	46.40	42.98	98.55	72.93	149.05
6	Other comprehensive income / (loss) for the period/year						
a	Items that will not be reclassified to profit and loss	0.41	(1.08)	(0.58)	(0.67)	(0.58)	(1.16)
b	Income tax effect on above item	(0.10)	0.27	0.15	0.17	0.15	0.29
	Other comprehensive income / (loss) for the period/year	0.31	(0.81)	(0.43)	(0.50)	(0.43)	(0.87)
7	Total comprehensive income for the period/year (5+6)	52.46	45.59	42.55	98.05	72.50	148.18
8	Paid-up equity share capital (face value Rs.10/-)	61.16	61.16	61.16	61.16	61.16	61.16
9	Other Equity						544.56
10	Earnings per share (not annualised for the quarter and half year)						
a	Basic (Rs.)	8.53	7.59	7.03	16.11	11.92	24.37
b	Diluted (Rs.)	8.53	7.59	7.03	16.11	11.92	24.37



Unaudited Statement of Standalone Assets and Liabilities as at 30 September 2025

(Amount Rs. in Crores)

Sr. No.	Particulars	As at 30 Sept. 2025 (Unaudited)	As at 31 March 2025 (Audited)
A	ASSETS:		
1	Non-current assets		
a	Property, plant and equipment	200.12	198.73
b	Capital work-in-progress	204.81	185.95
c	Other intangible assets	167.98	171.15
d	Financial assets		
i	Investments	25.37	25.34
ii	Loans	0.01	0.03
iii	Other financial assets	27.23	1.25
e	Other non-current assets	4.63	7.92
	Total non-current assets	630.15	590.37
2	Current assets		
a	Inventories	107.30	129.48
b	Financial assets		
i	Trade receivables	160.08	118.29
ii	Cash and cash equivalents	1.80	3.22
iii	Bank balances other than cash and cash equivalents	52.16	66.05
iv	Loans	0.19	0.38
v	Other financial assets	11.10	2.64
c	Other current assets	13.23	18.81
	Total current assets	345.86	338.87
	TOTAL ASSETS	976.01	929.24
B	EQUITY AND LIABILITIES:		
1	Equity		
a	Equity share capital	61.16	61.16
b	Other equity	597.90	544.56
	Total equity	659.06	605.72
	Liabilities		
2	Non-current liabilities		
a	Financial liabilities		
i	Borrowings	-	16.00
ii	Lease liabilities	20.28	21.02
b	Provisions	44.36	38.61
c	Deferred tax liabilities (net)	9.93	8.30
	Total non-current liabilities	74.57	83.93
3	Current liabilities		
a	Financial liabilities		
i	Borrowings	39.58	46.70
ii	Lease liabilities	2.85	2.52
iii	Trade payables		
	- total outstanding dues of micro enterprises and small enterprises	6.83	2.91
	- total outstanding dues of creditors other than micro enterprise and small enterprise	133.92	140.61
iv	Other financial liabilities	4.67	4.77
b	Other current liabilities	10.66	8.37
c	Provisions	30.00	27.39
d	Current tax liabilities (net)	13.87	6.32
	Total current liabilities	242.38	239.59
	Total liabilities	316.95	323.52
	TOTAL EQUITY AND LIABILITIES	976.01	929.24



Unaudited Statement of Standalone Cash Flows for the Half Year ended 30 September 2025 (Amount Rs. in Crores)		
Particulars	For Half Year ended Sept.2025 (Unaudited)	For Half Year ended Sept.2024 (Unaudited) (Refer note 4)
Cash flow from operating activities		
Profit before tax	130.50	96.64
Adjustments for:		
Depreciation and amortization expenses	18.12	17.43
Finance costs	3.92	6.02
Interest income	(2.76)	(2.75)
Fair valuation adjustments of Investments designated as Fair Value through Profit & Loss (FVTPL)	(0.04)	(0.01)
Loss on sale/disposal of fixed assets	0.43	0.06
Provision for expected credit loss*	0.05	0.00
Provision for inventory obsolescence written back	(1.03)	(0.47)
Bad debts written off	0.05	0.01
Liabilities written back	(0.06)	(0.12)
Provision for expiry and breakage sales return	4.83	4.11
Net Unrealized exchange Gain	(0.24)	(0.04)
Operating profit before working capital changes	153.77	120.88
Changes in working capital		
Decrease/ (Increase) in inventories	23.22	(8.30)
Increase in trade receivables	(41.66)	(26.77)
Decrease / (Increase) in other current assets	5.58	(0.36)
Increase in other financial assets	(8.51)	(0.12)
Decrease in non-current assets	0.04	0.15
Decrease in loans	0.21	0.24
Increase in other financial liabilities	0.96	0.64
Increase in provisions	2.86	1.51
(Decrease) / Increase in trade payables	(2.72)	25.26
Increase in other current liabilities	2.29	7.28
Cash generated from operations	136.04	120.41
Income taxes paid (Net)	(22.60)	(15.64)
Net cash generated from operating activities (A)	113.44	104.77
Cash flow from Investing activities		
Payment for property, plant and equipment and intangible assets including capital work-in-progress, capital advance and capital payable	(32.51)	(40.80)
Proceeds from sale/ disposal of fixed assets	0.47	0.20
Fixed deposits placed with Bank not considered as Cash and cash equivalents-Net	(12.04)	15.31
Interest received	2.76	2.75
Net cash (used in) investing activities (B)	(41.32)	(22.54)
Cash flow from Financing activities		
Payment of dividend	(44.71)	(22.63)
Repayment of long-term borrowings	(18.00)	(33.00)
Net decrease in working capital borrowings	(5.11)	(19.87)
Interest paid	(3.27)	(4.84)
Payment towards lease liability (excluding interest)	(1.37)	(1.14)
Interest on lease liability	(1.09)	(1.18)
Net cash (used in) from financing activities (C)	(73.55)	(82.66)
Net (decrease) in cash and cash equivalents (A+B+C)	(1.43)	(0.43)
Effect of exchange differences on restatement of foreign currency Cash and cash equivalents**	0.01	0.00
Cash and cash equivalents at the beginning of the period	3.22	3.16
Cash and cash equivalents at the end of the period	1.80	2.73

* Provision for expected credit loss for half year ended September 2024 represents amounting Rs.30,000/-

**Effect of exchange differences on restatement of foreign currency Cash and cash equivalents for half year ended September 2024 represents amounting Rs.33,835/-


Particulars	For Half Year ended Sept.2025 (Unaudited)	For Half Year ended Sept.2024 (Unaudited) (Refer note 4)
Cash and cash equivalents comprise		
Balances with banks:		
In current accounts	0.30	0.24
Cheques on hand	1.45	2.29
Cash on hand	0.05	0.20
Total cash and bank balances at end of the period	1.80	2.73



Notes to unaudited standalone financial results for the Quarter and Half Year ended 30 September 2025 :

- 1 The Company's equity shares have been listed on the National Stock Exchange of India ("NSE") and on BSE Limited ("BSE") on 15 December, 2025, by completing Initial Public Offering through offer for sale of 61,74,051 equity shares of face value of Rs.10 each at an issue price of Rs.1,008 per equity share (for employees) and Rs.1,062 per equity share (other than employees) by selling shareholders. The total initial public offer expenses (except listing fees) are entirely allocated to the selling shareholders. As the Company's equity shares were listed on 15 December 2025, this statement of unaudited standalone financial results for the quarter and half year ended 30 September 2025 is prepared for the first time in compliance with Regulation 33 of Securities and Exchange Board of India [Listing Obligations and Disclosure Requirements] Regulations, 2015, as amended.
- 2 The above unaudited standalone financial results have been reviewed by the Audit Committee and subsequently approved by Board of Directors at their respective meetings held on 02 January 2026. The Statutory Auditors have carried out limited review of the aforesaid results.
- 3 These unaudited standalone financial results have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 ["Ind AS"] as prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India [Listing Obligations and Disclosure Requirements] Regulations, 2015, as amended.
- 4 The financial results for the quarter ended 30 September 2024 and the half year ended 30 September 2024 have not been subject to limited review. However the management has exercised necessary diligence to ensure that the financial results for those periods provide a true and fair view of the Company's affairs.
- 5 The standalone financial results for the quarter ended 30 June 2025 have been extracted from the audited special purpose interim financial statements which were prepared for IPO filings.
- 6 The Company has only one reportable business segment i.e. 'Pharmaceuticals'.
- 7 The Ministry of Labour & Employment (MoLE), Government of India, has announced the implementation of four Labour Codes viz. the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020 (Collectively "The Labour Codes"), effective 21 November 2025. The Company is in the process of assessing the impact of such changes. Since the Labour Codes are effective from 21 November 2025, they do not have any implication on the results for the quarter and half year ended 30 September 2025.

For CORONA Remedies Limited,



Nirav K. Mehta
Managing Director & CEO
DIN : 01644041

Place: Ahmedabad
Date : 02 January 2026



INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF CORONA REMEDIES LIMITED (FORMELY KNOWN AS CORONA REMEDIES PRIVATE LIMITED)

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **CORONA Remedies Limited (formerly known as CORONA Remedies Private Limited)** ("the Parent") and its share of the net profit/(loss) after tax and total comprehensive income/(loss) of its associate for the quarter and half year ended September 30, 2025 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. The Statement includes the results of the following entities:
 - a) CORONA Remedies Limited (formerly known as CORONA Remedies Private Limited) - Parent
 - b) La Chandra Pharma Labs Private Limited - Associate
5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



**Deloitte
Haskins & Sells LLP**

6. The unaudited consolidated financial results include the Parent's share of profit/(loss) after tax of Rs 0.17 Crores and Rs (0.03) Crores for the quarter and half year ended September 30, 2025 respectively and total comprehensive income/(loss) of Rs.0.17 Crores and Rs (0.03) Crores for the quarter and half year ended September 30, 2025 respectively, as considered in the Statement, in respect of 1 associate, based on their interim financial information which have not been reviewed by its auditor. According to the information and explanations given to us by the Management, this interim financial information is not material to the unaudited consolidated financial results.

Our conclusion on the Statement is not modified in respect of our reliance on the financial information certified by the Management.

7. As stated in Note 4 to the Statement, financial information relating to the quarter and half year ended September 30, 2024 included in the Statement have been furnished to us by the Management and have not been subjected to review by us.

Our conclusion on the Statement is not modified in respect of this matter.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



H. S. Sutaria

Hardik Sutaria
Partner
Membership No. 116642
UDIN: 26116642NREZGK6570

Place: Ahmedabad
Date: January 02, 2026




CORONA Remedies Limited
(formerly known as CORONA Remedies Private Limited)
Regd. Office: CORONA House,
C - Mondeal Business Park, Near Gurudwara, S.G.Highway,
Thaltej, Ahmedabad-380059, Gujarat, India
Tel.: +079-40233000 | Website : www.coronaremedies.com
CIN : L24231GJ2004PLC044656

Statement of Unaudited Consolidated Financial Results for the Quarter and Half Year ended 30 September 2025

(Amount Rs. in Crores except per share data)

Sr. No.	Particulars	For Quarter Ended			For Half Year Ended		For Year Ended
		30 Sept. 2025 (Unaudited)	30 June 2025 (Audited) (Refer note 5)	30 Sept. 2024 (Unaudited) (Refer note 4)	30 Sept. 2025 (Unaudited)	30 Sept. 2024 (Unaudited) (Refer note 4)	31 March 2025 (Audited)
1	Income :						
a	Revenue from operations	361.13	346.54	313.87	707.67	605.04	1,196.42
b	Other income	2.27	2.02	2.46	4.29	3.75	5.93
	Total income	363.40	348.56	316.33	711.96	608.79	1,202.35
2	Expenses :						
a	Cost of materials consumed	25.90	25.07	28.56	50.97	51.69	102.29
b	Purchases of Stock-in-trade	28.11	34.77	41.94	62.88	77.02	157.97
c	Changes in inventories of finished goods, stock-in-trade and work-in-progress	14.64	5.94	(7.90)	20.58	(4.25)	(23.74)
d	Employee benefits expense	103.00	97.44	87.82	200.44	171.82	346.14
e	Finance costs	1.93	1.99	2.87	3.92	6.02	10.60
f	Depreciation and amortization expenses	9.20	8.92	9.05	18.12	17.43	37.16
g	Other expenses	111.01	113.54	96.63	224.55	192.42	373.78
	Total expenses	293.79	287.67	258.97	581.46	512.15	1,004.20
3	Profit before tax and share of profit of Associate (1-2)	69.61	60.89	57.36	130.50	96.64	198.15
4	Share of Profit / (Loss) of Associate (net of tax)	0.17	(0.20)	(0.01)	(0.03)	(0.01)	0.38
5	Profit before tax (3+4)	69.78	60.69	57.35	130.47	96.63	198.53
6	Tax expense :						
a	Current tax expense	15.85	15.19	12.89	31.04	22.22	45.55
b	(Excess) provision for tax relating to earlier periods / year	-	(0.89)	(0.75)	(0.89)	(0.75)	(0.75)
c	Deferred tax expense / (income)	1.61	0.19	2.24	1.80	2.24	4.30
	Tax expense	17.46	14.49	14.38	31.95	23.71	49.10
7	Net Profit after tax for the period / year (5-6)	52.32	46.20	42.97	98.52	72.92	149.43
8	Other comprehensive income / (loss) for the period/year						
a	Items that will not be reclassified to profit and loss	0.41	(1.08)	(0.58)	(0.67)	(0.58)	(1.16)
b	Income tax effect on above item	(0.10)	0.27	0.15	0.17	0.15	0.29
	Other comprehensive income / (loss) for the period/year	0.31	(0.81)	(0.43)	(0.50)	(0.43)	(0.87)
9	Total comprehensive income for the period/year (7+8)	52.63	45.39	42.54	98.02	72.49	148.56
10	Profit for the year/period attributable to:						
	Owners of the Company	52.32	46.20	42.97	98.52	72.92	149.43
		52.32	46.20	42.97	98.52	72.92	149.43
11	Total Other Comprehensive (loss) for the period/year attributable to:						
	Owners of the Company	0.31	(0.81)	(0.43)	(0.50)	(0.43)	(0.87)
		0.31	(0.81)	(0.43)	(0.50)	(0.43)	(0.87)
12	Total Comprehensive Income for the period/year attributable to:						
	Owners of the Company	52.63	45.39	42.54	98.02	72.49	148.56
		52.63	45.39	42.54	98.02	72.49	148.56
13	Paid-up equity share capital (face value Rs.10/-)	61.16	61.16	61.16	61.16	61.16	61.16
14	Other Equity						545.18
15	Earnings per share (not annualised for the quarter and half year)						
a	Basic (Rs.)	8.55	7.55	7.03	16.11	11.92	24.43
b	Diluted (Rs.)	8.55	7.55	7.03	16.11	11.92	24.43



Unaudited Statement of Consolidated Assets and Liabilities as at 30 September 2025

(Amount Rs. in Crores)

Sr. No.	Particulars	As at 30 Sept. 2025 (Unaudited)	As at 31 March 2025 (Audited)
A	ASSETS:		
1	Non-current assets		
a	Property, plant and equipment	200.12	198.73
b	Capital work-in-progress	204.81	185.95
c	Other intangible assets	167.98	171.15
e	Investments accounted using equity method	25.82	25.85
f	Financial assets		
i	Investments	0.14	0.11
ii	Loans	0.01	0.03
iii	Other financial assets	27.23	1.25
g	Other non-current assets	4.63	7.92
	Total non-current assets	630.74	590.99
2	Current assets		
a	Inventories	107.30	129.48
b	Financial assets		
i	Trade receivables	160.08	118.29
ii	Cash and cash equivalents	1.80	3.22
iii	Bank balances other than cash and cash equivalents	52.16	66.05
iv	Loans	0.19	0.38
v	Other financial assets	11.10	2.64
c	Other current assets	13.23	18.81
	Total current assets	345.86	338.87
	TOTAL ASSETS	976.60	929.86
B	EQUITY AND LIABILITIES:		
1	Equity		
a	Equity share capital	61.16	61.16
b	Other equity	598.49	545.18
	Total equity	659.65	606.34
	Liabilities		
2	Non-current liabilities		
a	Financial liabilities		
i	Borrowings	-	16.00
ii	Lease liabilities	20.28	21.02
b	Provisions	44.36	38.61
c	Deferred tax liabilities (net)	9.93	8.30
	Total non-current liabilities	74.57	83.93
3	Current liabilities		
a	Financial liabilities		
i	Borrowings	39.58	46.70
ii	Lease liabilities	2.85	2.52
iii	Trade payables		
	- total outstanding dues of micro enterprises and small enterprises	6.83	2.91
	- total outstanding dues of creditors other than micro enterprise and small enterprise	133.92	140.61
iv	Other financial liabilities	4.67	4.77
b	Other current liabilities	10.66	8.37
c	Provisions	30.00	27.39
d	Current tax liabilities (net)	13.87	6.32
	Total current liabilities	242.38	239.59
	Total liabilities	316.95	323.52
	TOTAL EQUITY AND LIABILITIES	976.60	929.86



Unaudited Statement of Consolidated Cash Flows for the Half Year ended 30 September 2025

(Amount Rs. in Crores)

Particulars	For Half Year ended Sept.2025 (Unaudited)	For Half Year ended Sept.2024 (Unaudited) (Refer note 4)
Cash flow from operating activities		
Profit before tax	130.47	96.63
Adjustments for:		
Share of loss / (profit) from Associate	0.03	0.01
Depreciation and amortization expenses	18.12	17.43
Finance costs	3.92	6.02
Interest income	(2.76)	(2.75)
Fair valuation adjustments of Investments designated as Fair Value through Profit & Loss (FVTPL)	(0.04)	(0.01)
Loss on sale/disposal of fixed assets	0.43	0.06
Provision for expected credit loss*	0.05	0.00
Provision for inventory obsolescence written back	(1.03)	(0.47)
Bad debts written off	0.05	0.01
Liabilities written back	(0.06)	(0.12)
Provision for expiry and breakage sales return	4.83	4.11
Net Unrealized exchange Gain	(0.24)	(0.04)
Operating profit before working capital changes	153.77	120.88
Changes in working capital		
Decrease/ (Increase) in inventories	23.22	(8.30)
Increase in trade receivables	(41.66)	(26.77)
Decrease / (Increase) in other current assets	5.58	(0.36)
Increase in other financial assets	(8.51)	(0.12)
Decrease in non-current assets	0.04	0.15
Decrease in loans	0.21	0.24
Increase in other financial liabilities	0.96	0.64
Increase in provisions	2.86	1.51
(Decrease) / Increase in trade payables	(2.72)	25.26
Increase in other current liabilities	2.29	7.28
Cash generated from operations	136.04	120.41
Income taxes paid (Net)	(22.60)	(15.64)
Net cash generated from operating activities (A)	113.44	104.77
Cash flow from Investing activities		
Payment for property, plant and equipment and intangible assets including capital work-in-progress, capital advance and capital payable	(32.51)	(40.80)
Proceeds from sale/ disposal of fixed assets	0.47	0.20
Fixed deposits placed with Bank not considered as Cash and cash equivalents-Net	(12.04)	15.31
Interest received	2.76	2.75
Net cash (used in) investing activities (B)	(41.32)	(22.54)
Cash flow from Financing activities		
Payment of dividend	(44.71)	(22.63)
Repayment of long-term borrowings	(18.00)	(33.00)
Net decrease in working capital borrowings	(5.11)	(19.87)
Interest paid	(3.27)	(4.84)
Payment towards lease liability (excluding interest)	(1.37)	(1.14)
Interest on lease liability	(1.09)	(1.18)
Net cash (used in) from financing activities (C)	(73.55)	(82.66)
Net (decrease) in cash and cash equivalents (A+B+C)	(1.43)	(0.43)
Effect of exchange differences on restatement of foreign currency Cash and cash equivalents**	0.01	0.00
Cash and cash equivalents at the beginning of the period	3.22	3.16
Cash and cash equivalents at the end of the period	1.80	2.73

* Provision for expected credit loss for half year ended September 2024 represents amounting Rs.30,000/-

**Effect of exchange differences on restatement of foreign currency Cash and cash equivalents for half year ended September 2024 represents amounting Rs.33,835/-

Particulars	For Half Year ended Sept.2025 (Unaudited)	For Half Year ended Sept.2024 (Unaudited) (Refer note 4)
Cash and cash equivalents comprise		
Balances with banks:		
In current accounts	0.30	0.24
Cheques on hand	1.45	2.29
Cash on hand	0.05	0.20
Total cash and bank balances at end of the period	1.80	2.73



Notes to unaudited consolidated financial results for the Quarter and Half Year ended 30 September 2025 :

- 1 The Company's equity shares have been listed on the National Stock Exchange of India ("NSE") and on BSE Limited ("BSE") on 15 December, 2025, by completing Initial Public Offering through offer for sale of 61,74,051 equity shares of face value of Rs.10 each at an issue price of Rs.1,008 per equity share (for employees) and Rs.1,062 per equity share (other than employees) by selling shareholders. The total initial public offer expenses (except listing fees) are entirely allocated to the selling shareholders. As the Company's equity shares were listed on 15 December 2025, this statement of unaudited consolidated financial results for the quarter and half year ended 30 September 2025 is prepared for the first time in compliance with Regulation 33 of Securities and Exchange Board of India [Listing Obligations and Disclosure Requirements] Regulations, 2015, as amended.
- 2 The above unaudited consolidated financial results of CORONA Remedies Limited [the 'Company'] and its associate have been reviewed by the Audit Committee and subsequently approved by Board of Directors at their respective meetings held on 02 January 2026. The Statutory Auditors have carried out limited review of the aforesaid results.
- 3 These unaudited consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 ["Ind AS"] as prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India [Listing Obligations and Disclosure Requirements] Regulations, 2015, as amended.
- 4 The financial results for the quarter ended 30 September 2024 and the half year ended 30 September 2024 have not been subject to limited review. However the management has exercised necessary diligence to ensure that the financial results for those periods provide a true and fair view of the Company's affairs.
- 5 The consolidated financial results for the quarter ended 30 June 2025 have been extracted from the audited special purpose interim financial statements which were prepared for IPO filings.
- 6 The Company and its associate has only one reportable business segment i.e. 'Pharmaceuticals'.
- 7 The Ministry of Labour & Employment (MoLE), Government of India, has announced the implementation of four Labour Codes viz. the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020 (Collectively "The Labour Codes"), effective 21 November 2025. The Company and its associate are in the process of assessing the impact of such changes. Since the Labour Codes are effective from 21 November 2025, they do not have any implication on the results for the quarter and half year ended 30 September 2025.

For CORONA Remedies Limited,



Nirav K. Mehta
Managing Director & CEO
DIN : 01644041

Place: Ahmedabad
Date : 02 January 2026



Press Release: CORONA Remedies Limited Q2 and H1 FY26 Results

The Consolidated Revenue from Operations for the quarter and half year for FY26 stood at **₹ 361.13 Cr. and ₹ 707.67 Cr.** respectively. The Revenue of the above periods grew by **15.1% and 17.0%** respectively, on Y-o-Y basis.

PAT for the quarter and half year FY26 was **₹ 52.32 Cr. and ₹ 98.52 Cr.** respectively. The PAT of the above periods grew by **21.8% and 35.1%** respectively, on Y-o-Y basis.

Ahmedabad, January 02, 2026: CORONA Remedies Limited, today announced the unaudited results for the second quarter and half year ended September 30, 2025, as approved by its Board of Directors.

Q2FY26 Financial Highlights:

Particulars (₹ in Cr.)	Q2FY26	H1FY26
Revenue from Operations	361.13	707.67
Gross Profit	292.48	573.24
EBITDA	78.47	148.25
EBITDA Margin	21.7%	20.9%
Profit After Tax	52.32	98.52
Profit After Tax Margin	14.5%	13.9%

H1 FY26 Key Financial Metrics:

Particulars	H1 FY26
RoE*	31.1%
RoCE*	49.7%
OCF to EBITDA	76.5%
Net Working Capital Days	23 Days

* Annualised

Commenting on the results, Mr. Nirav K. Mehta, Managing Director and CEO, CORONA Remedies Limited, said:

“We are delighted to report a strong financial performance in Q2 and H1 FY26. Revenues for Q2 and H1FY26 grew by 15.1% and 17.0% respectively on a Y-o-Y basis, outperforming the IPM growth. Profit after tax for Q2 and H1FY26 grew by 21.8% and 35.1% respectively on a Y-o-Y basis while maintaining healthy return ratios.

Our strong performance reflects the consistency of our strategy, disciplined execution and deep focus on our core therapeutic segments. By strengthening our field force, expanding our brand portfolio and maintaining a sharp focus on specialists prescriptions, we have continued to outperform the market while building a sustainable platform for long-term growth.

Lastly, we are grateful to our bankers for their efforts in the successful listing of CORONA on the Indian stock exchanges. I would also like to thank the entire team at CORONA and our stakeholders for their continued support and faith in our business.”

Earnings Call:

CORONA Remedies Limited will conduct earnings call at 12:00 PM (IST) on January 05, 2026 to discuss the financial and business performance of the quarter. To participate in this conference call, please dial the numbers provided below ten minutes ahead of the scheduled start time.

Date & Time	Monday, January 05, 2026 12:00 PM IST 01:30 AM USA EDT 06:30 AM UK TIME 02:30 PM HK/SINGAPORE TIME
Universal Dial In	+91-22-6280 1366 / +91-22-7115 8267
International Dial In	USA: 1 866 746 2133 UK: 0 808 101 1573 Singapore: 800 101 2045 Hong Kong: 800 964 448
Diamond Pass Link	https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=9127751&linkSecurityString=47bf57b320

About CORONA Remedies Limited:

CORONA Remedies Limited (CORONA), founded in 2004, is an India focused branded pharmaceutical formulation company engaged in developing, manufacturing and marketing products in women's healthcare, cardio-diabeto, pain management, urology and other therapeutic areas.

CORONA manufactures products for healthcare solutions as per international quality standards in its WHO-GMP/ EU GMP-certified plant. CORONA has 2 DSIR-approved R&D centres with 100+ team members including scientists working on new formulation development. CORONA is a proud family of 4500+ employees.

To know more about us, visit www.coronaremedies.com

For further information, please contact: Mr. Sagar Shroff, Strategic Growth Advisors Private Limited (SGA), Mobile: 98205 19303 and Email Id: sagar.shroff@sgapl.net

Disclaimer: Certain statements contained in this document may be statements of future expectations and other forward-looking statements that are based on management's current view and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. None of CORONA Remedies Limited or any of its affiliates, advisors or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this document or its content or otherwise arising in connection with this document. This document does not constitute an offer or invitation to purchase or subscribe for any shares and neither it nor any part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever.
